Small Cell Lung Cancer (SCLC) is fast-growing lung cancer. It usually starts in the bronchi (center of the chest). Though the cancer cells are small, but they grow aggressively and create large tumors. These kinds of tumors often metastasize quickly to other parts of the body. SCLC has two stages such as; limited-stage and extensive-stage. The primary goal of staging in Small Cell Lung Cancer is to determine whether cancer has spread or not.
There are several risk factors that can lead to the development of SCLC. The primary risk factor of SCLC is tobacco use; almost all affected individuals smoke or have a history of smoking. In addition to this, the symptoms can vary from one person to another, and there are rarely any symptoms early in the course of the disease. The diagnosis of SCLC is based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market
The Small Cell Lung Cancer market report also covers emerging drugs, current treatment practices, Small Cell Lung Cancer market share of the individual therapies, current and forecasted Small Cell Lung Cancer Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Small Cell Lung Cancer Market Key Facts
Total incident cases of Small Cell Lung Cancer (SCLC) in the 7MM were assessed to be 85,540 in 2017, and are expected to increase during the study period.
Among the 7MM, most Incident cases of Small Cell Lung Cancer (SCLC) were recorded in the United States.
Among the European 5 countries, Germany had the highest incident population of Small Cell Lung Cancer, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of SCLC in 2017. Furthermore, Japan accounts for 21% of the 7MM patient population of SCLC.
Key Benefits of Small Cell Lung Cancer Market Report
-
Small Cell Lung Cancer market report provides an in-depth analysis of Small Cell Lung Cancer Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Small Cell Lung Cancer market report will help in developing business strategies by understanding the Small Cell Lung Cancer Market trends & developments, key players, and future market competition that will shape and drive the Small Cell Lung Cancer market in the upcoming years.
-
The Small Cell Lung Cancer market report covers Small Cell Lung Cancer current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Small Cell Lung Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Extensive-Stage Small Cell Lung Cancer market size in the 7MM is expected to increase by 2030 from USD 337 million in 2017.
Small Cell Lung Cancer market size is expected to increase during the forecast period owing to the increasing incident case of Small Cell Lung Cancer, mainly due to increase in geriatric population, expected entry of potential premium price emerging therapies, and readily uptake of currently approved immunotherapies across the 7MM.
The Small Cell Lung Cancer market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Small Cell Lung Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Small Cell Lung Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Small Cell Lung Cancer Epidemiology
In 2017, a more number of males were affected by the disease, i.e., 55% of the SCLC cases in the 7MM, in comparison to the females. However, the incidence gap between males and females has narrowed over the past three decades.
The Small Cell Lung Cancer epidemiology section covers insights about the historical and current Small Cell Lung Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Small Cell Lung Cancer Drugs Uptake and Key Market Players
The Small Cell Lung Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Small Cell Lung Cancer market or expected to get launched in the market during the study period. The analysis covers Small Cell Lung Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Given the nature and difficulty of SCLC compared to NSCLC and the lack of treatment options, there are significant unmet needs for patients suffering from Small Cell Lung Cancer. There are several therapies in the pipeline which can improve the current scenario of the Small Cell Lung Cancer treatment paradigm in the upcoming future.
The dynamics of the Small Cell Lung Cancer (SCLC) market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.
Small Cell Lung Cancer (SCLC) companies involved in therapeutics development include:
AstraZeneca
G1 Therapeutics
United Therapeutics
EpicentRx
Amgen
Fate Therapeutics
Takeda
PharmaMar
And many others.
Small Cell Lung Cancer therapies covered in the report include:
Imfinzi
Trilaciclib (G1T28)
Dinutuximab
RRx-001
Lurbinectedin
AMG 757
AMG 119
Ponatinib
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Small Cell Lung Cancer Competitive Intelligence Analysis
4. Small Cell Lung Cancer Market Overview at a Glance
5. Small Cell Lung Cancer Disease Background and Overview
6. Small Cell Lung Cancer Patient Journey
7. Small Cell Lung Cancer Epidemiology and Patient Population
8. Small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of Small Cell Lung Cancer Treatment
11. Small Cell Lung Cancer Marketed Products
12. Small Cell Lung Cancer Emerging Therapies
13. Small Cell Lung Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Small Cell Lung Cancer Market Outlook (7 major markets)
16. Small Cell Lung Cancer Access and Reimbursement Overview
17. KOL Views on the Small Cell Lung Cancer Market.
18. Small Cell Lung Cancer Market Drivers
19. Small Cell Lung Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Small Cell Lung Cancer Epidemiology Forecast
DelveInsight's Small Cell Lung Cancer - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of SCLC in the 7MM.
Small Cell Lung Cancer Pipeline Insights
Small Cell Lung Cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Small Cell Lung Cancer market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
